Skip to main content
TipRanks
Go Ultimate75% OFF

Avenue Therapeutics (ATXI) AI Stock Analysis

334 Followers
ATXI

Avenue Therapeutics

(Other OTC:ATXI)

Select Model
Rating:38Underperform
Price Target:$0.26â–¼(-6.07% Downside)
Action:downgraded
Date:11/13/26

The score is driven primarily by severe financial weakness, including no revenue, negative equity, and ongoing cash burn. Bearish technical positioning and the absence of valuation support reinforce the highly speculative profile, despite oversold momentum readings.

Positive Factors
Debt-free balance sheetThe absence of debt reduces financial leverage and interest-burden risk, leaving fewer mandatory claims on future cash flows. Although the company remains financially constrained, a debt-free structure can provide more flexibility than a highly leveraged balance sheet if funding or partnership opportunities emerge.
Negative Factors
No current recurring revenueThe return to zero trailing-twelve-month revenue indicates that commercial traction is not currently dependable. Without recurring product or partnership revenue, the company has limited internal funding capacity and remains exposed to delays in approvals, licensing, or future commercialization.

Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%ATXI-65.64%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.28M
Dividend Yield
―
Average Volume (3M)
8,934
Price to Earnings (P/E)
-0.3
Beta (1Y)
0.99
Revenue Growth
-100.00%
EPS Growth
42.53%
Country
US
Employees
1
Sector
General
Sector Strength
55
Industry
Biotechnology

Avenue Therapeutics Business Overview & Revenue Model

Company Description

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product c...

How the Company Makes Money

Avenue Therapeutics’ ability to generate revenue is primarily tied to monetizing its drug-development programs rather than diversified operating businesses. In general, the company can make money through (i) collaboration, licensing, or commercializa...

Avenue Therapeutics Financial Statement Overview

Summary

Very weak performance: zero revenue, recurring losses, negative TTM equity, and continued cash burn. Debt-free status and reduced losses provide limited support.

Income Statement

7Very Negative

Balance Sheet

24Negative

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue01.40M0000
Gross Profit-1.40M1.40M0000
EBITDA-3.08M-3.29M-11.70M4.05M-2.44M7,000
Net Income-2.79M-2.91M-11.65M-10.38M-3.55M-3.73M
Balance Sheet
Total Assets1.53M2.93M2.67M1.85M6.84M3.96M
Cash, Cash Equivalents and Short-Term Investments1.52M2.85M2.59M1.78M6.71M3.76M
Total Debt000000
Total Liabilities1.60M1.10M816.00K1.20M3.58M509.00K
Stockholders Equity-75.00K1.83M2.80M1.58M3.90M3.45M
Cash Flow
Free Cash Flow-2.19M-1.83M-9.03M-12.45M-7.60M-3.75M
Operating Cash Flow-2.19M-1.83M-9.03M-9.45M-7.60M-3.75M
Investing Cash Flow000-3.00M00
Financing Cash Flow02.09M9.84M7.53M10.54M4.38M

Avenue Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.28

Price Trends

50DMA0.44Negative
100DMA0.38Negative
200DMA0.36Negative

Market Momentum

MACD-0.03Positive
RSI33.31Neutral
STOCH4.50Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.44, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 33.31 is Neutral, neither overbought nor oversold. The STOCH value of 4.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATXI.

Avenue Therapeutics Risk Analysis

Avenue Therapeutics disclosed 65 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Fortress' current or future financial obligations and arrangements, or an event of default thereon, may change the ownership dynamic of us by Fortress.Q4, 2023
2.If we experience delays or difficulties in the enrollment of patients in any future clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.Q4, 2023
3.The making, use, sale, importation, exportation, and distribution of controlled substances are subject to regulation by state, federal, and foreign law enforcement and other regulatory agencies.Q4, 2023

Avenue Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

ATXI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ADXNADXN44Neutral$4.89M-0.69-172.76%―-45.76%-3.77%
CTXRCTXR43Neutral$14.69M-0.25-67.15%――57.48%
ENSCENSC40Underperform$8.14M-0.07-1232.64%―37.91%1.72%
SKYESKYE40Underperform$4.83M-0.14-503.95%――26.40%
CALCCALC39Underperform$8.34M-0.27-3029.57%――45.29%
ATXIATXI38Underperform$922.59K-0.33-316.12%―-100.00%42.53%

* General Sector Average

Performance Comparison

-50%0%50%100%ATXIENSCCTXRSKYECALCADXNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ATXI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ATXIAvenue Therapeutics0.28-0.52-65.00%
ENSCEnsysce Biosciences, Inc.0.42-1.54-78.67%
CTXRCitius Pharma0.54-0.40-42.78%
SKYESkye Bioscience, Inc.1.09-10.11-90.27%
CALCCalcimedica, Inc.1.21-14.51-92.30%
ADXNAddex Therapeutics Ltd (ADR)4.06-4.34-51.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026